Our Vision of Covalent as Developer of Catabody Drugs and E-Vaccines
Our broadly enabling technology platform has provided multiple lead and pipeline products we think will be clinically successful. For focused product development, we plan to spinout the HIV E-Vaccine into a separate company. Covalent’s initial clinical focus is the anti-aging catabody Cardizyme. Additional spinouts are likely with progress in clarifying the utility of the individual lead products, e.g., the Alzheimer catabodies Partnerships with Pharma companies that have late-stage development/marketing expertise are welcome.